Ownership and insider activity for NeuroPace, Inc. (NPCE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.
Price
| Price | $14.10 |
| Market Cap | $481M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.1M | $26.4M | $19.2M | $6.6M | $18.1M | $13.4M | $21.7M |
| Short-term Investments | $969000 | $11.7M | $96.4M | $70.8M | $48.4M | $39.3M | $39.4M |
| Receivables | $6.0M | $8.4M | $7.1M | $7.5M | $12.3M | $12.9M | $14.7M |
| Inventory | $7.9M | $6.9M | $7.8M | $9.7M | $11.2M | $13.4M | $16.9M |
| Total Current Assets | $20.3M | $54.6M | $132.8M | $97.7M | $92.7M | $81.3M | $94.1M |
| Property, Plant & Equipment | $810000 | $515000 | $603000 | $15.9M | $14.4M | $12.9M | $11.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $21.1M | $56.0M | $133.6M | $114.1M | $107.7M | $94.6M | $105.6M |
| Accounts Payable | $903000 | $949000 | $1.4M | $2.1M | $2.3M | $3.0M | $2.2M |
| Short-term Debt | $62.8M | $2.0M | 0 | 0 | 0 | 0 | $2.1M |
| Total Current Liabilities | $75.1M | $9.6M | $9.3M | $11.0M | $16.2M | $15.2M | $17.8M |
| Long-term Debt | 0 | $50.8M | $49.8M | $52.9M | $57.0M | $59.5M | $58.9M |
| Total Liabilities | $150.4M | $203.8M | $60.1M | $79.3M | $87.0M | $86.6M | $86.5M |
| Retained Earnings | -$363.6M | -$387.7M | -$423.8M | -$470.9M | -$503.8M | -$531.0M | -$552.4M |
| Total Equity | -$129.3M | -$147.8M | $73.5M | $34.8M | $20.7M | $8.0M | $19.0M |
| Total Debt | $62.8M | $52.9M | $49.8M | $69.8M | $72.4M | $73.3M | $70.8M |
| Net Debt | $57.7M | $14.8M | -$65.7M | -$7.6M | $5.9M | $20.6M | $9.8M |
| Working Capital | -$54.9M | $45.0M | $123.5M | $86.7M | $76.5M | $66.2M | $76.3M |
Financial Health
| Debt / Equity | 5.88 |
| Current Ratio | 4.94 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -2.52 |
Profitability
| Return on Equity | -119.68% |
| Return on Invested Capital | -18.43% |
| Return on Assets | -19.71% |
| Gross Margin | 79.63% |
| Operating Margin | -15.26% |
| Net Margin | -19.34% |
Explore sector: Healthcare · Medical - Devices
More sections of NPCE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks